Base editors

| CRISPR Medicine | This is an overview of articles on base editors

Sign-up to weekly Newsletter here.

Base editors

| CRISPR Medicine | This is an overview of articles on base editors

Sign-up to weekly Newsletter here.

Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-dependent Beta- Thalassemia, (NCT06479616)
Sponsors:
Children's Hospital of Fudan University
IND Enabling
Phase I
Phase II
Phase III
Retinitis Pigmentosa, (NCT06952842)
Sponsors:
Chigenovo Co., Ltd
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, (NCT07000318)
Sponsors:
Children's Hospital of Fudan University
Indicator
IND Enabling
Phase I
Phase II
Phase III
X-Linked Severe Combined Immunodeficiency, (NCT06851767)
Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
CD40L-HyperIgM Syndrome, (NCT06959771)
Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed/​Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma, (NCT06934382)
Sponsors:
Stephan Grupp MD PhD, Children's Hospital of Philadelphia
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine